FDA says benefit uncertain for Pfizer PNET drug, as Novartis narrows sNDA before ODAC
This article was originally published in Scrip
Executive Summary
Just days before a US FDA advisory panel is set to review a supplemental new drug application (sNDA) for Novartis' Afinitor (everolimus), the Swiss drug maker narrowed the indication it is seeking.